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Heme–PrP complexPrion protein (PrP) binding to natural and synthetic porphyrins has been previously demonstrated but the effects
of endogenous heme interactionswith PrP remain uncertain. This study investigated implications of this interac-
tion in blood-based peroxidase-linked prion immunodetection and seeded conversion of cellular prion (PrPC)
into disease associated form (PrPSc). Heme binding to recombinant PrPC enhanced intrinsic peroxidase activity
(POD) by 2.5-fold and POD inherent to denatured blood accounted for over 84% of luminol-based substrate oxi-
dation in a prion immunodetection assay. An immuno-capture assay showed that 75–98% of blood POD was at-
tributable to binding of PrPC with endogenous heme. Additionally, 10 μM heme inhibited (P b 0.05) the seeded
conversion of PrPC to PrPSc through the protein misfolding cycling ampliﬁcation assay. We conclude that the ob-
served effects can interferewith cell-free conversion and peroxidase-linked immunodetection of prions in blood-
based assays. These results indicate that heme–PrP interactions could modulate intrinsic POD and protect PrPC
from conversion into PrPSc.
Crown Copyright © 2015 Published by Elsevier Ltd. All rights reserved.1. Introduction
The prion protein (PrP) is a GPI (glycosylphosphatidylinositol)-
linked cell-surface glycoprotein expressed primarily by cells of the cen-
tral and peripheral nervous system and the lymphoreticular system.
During prion disease, the normal cellular isoform (PrPC) undergoes sev-
eral structural modiﬁcations to become a disease-speciﬁc conformation
(PrPSc), which is believed to be the causative agent of a group of
transmissible spongiform encephalopathies (Prusiner, 1998). The ap-
pearance of prion infectivity and PrPSc within different peripheral lym-
phoid tissues during natural scrapie infection in sheep suggests a
haematogenous route of dissemination. For this to occur, blood cells
may harbor or carry PrPSc and in doing so present altered conformations
of PrP on their cell-surface (Thackray et al., 2005). Indeed, Edwards et al.
found that a subset of peripheral blood mononuclear cells is most likely
to sequester and contribute to the trafﬁcking of PrPSc to the spleen dur-
ing early pathogenesis of the disease (Edwards et al., 2010). Previously,
it was demonstrated that resting humanplatelets express approximate-
ly 600 to 800molecules of PrPC per cell and the level of PrPC on red blood
cells (RBC) is four times lower than on platelets (Holada and Vostal,
2000; Panigaj et al., 2011). However, based on total cell counts in the en-
tire blood volume (Wilhelmi et al., 2012), human RBC are thought toeld), Canadian Food Inspection
Canada. Tel.: +1 343 212 0264.
Soutyrine).
r Ltd. All rights reserved.carry at least twice as much PrPC compared to platelets, making them
the main source of cell-associated PrPC in blood (Panigaj et al., 2011).
A major component of the RBC is hemoglobin, a protein containing
the natural iron-protoporphyrin IX complex, which exists in either the
Fe3+ (hemin) or Fe2+ (heme) oxidation state (Caughey et al., 1975).
Recent ﬁndings suggest that PrP may participate in heme-dependent
biological events and that heme binding is relevant in PrP functions
(Lee et al., 2007). Cellular PrP, after being post-translationally processed
in the endoplasmic reticulum and Golgi, is expressed on the cell surface
or can cycle between the cell membrane and endosomal compartments
(Harris, 2003). It is thought that during biogenesis or endocytic trafﬁck-
ing, PrP may interact with intracellular heme. Multiple hememolecules
can bind directly to PrP, primarily via its N-terminal half (Lee et al.,
2007) by inserting ﬁve hemes between the tyrosine aromatic rings of
the PrP globular domain or by binding two hemes to the leading ﬂexible
fragment of PrP (Pato et al., 2004).
Some effects of PrP binding to the synthetic or natural porphyrins
have been demonstrated. Synthetic porphyrins have been shown to
bind to PrP, which led to the inhibition of PrPSc formation in vitro
(Caughey et al., 1998) and strong prophylactic anti-scrapie activities
in vivo (Priola et al., 2000). At the same time, hemin was reported to in-
duce aggregation and decrease PrPC solubility (Lee et al., 2007).Wenote
this interesting phenomenonwhereby porphyrin compoundsmay both
inhibit conversion of PrPC to PrPSc, but yet contribute to the generation
of stacked, PrPC insoluble (iPrPC) oligomers.
Recently it has been shown that a recombinant PrPC treated with
commercial hemin can increase the inherent peroxidase activity
169A. Soutyrine et al. / Research in Veterinary Science 101 (2015) 168–174(POD) of heme (Lee et al., 2007). Drawing a parallel with other amyloid
peptides causing neurodegeneration, earlier studies have also revealed
strong anti-oxidant and anti-ﬁbrillogenic activity of the heme–
amyloid-β complex (Atamna and Boyle, 2006; Howlett et al., 1997;
Khodarahmi et al., 2010). Certain antioxidant enzymes possessing
POD have been shown to play a major role in the detoxiﬁcation of per-
oxides in brain (Kish et al., 1985), may inﬂuence oxidative stress resis-
tance (Zachara et al., 2006) and have been found to be lowered during
prion infection (Milhavet et al., 2000). A relationship between neurode-
generation caused by lack of antioxidant defense (Brown et al., 1999)
and oxidative stress leading to the conversion of PrPC intomisfolded iso-
forms (Redecke et al., 2007) may be predicted.
Hemoprotein complexes are known for their catalytic potential (Das
and Hecht, 2007). Early studies showed that certain hemoproteins ac-
quire elevated oxidation activity when denatured (Eriksson et al.,
1971; Yamada et al., 2002). It remains unclear to what extent the in-
creased exposure of PrP-bound heme can contribute to POD in blood
and body tissues. Porphyrins have also been shown to possess anti-
ﬁbrillogenic effects, but the ability of heme to prevent the conversion
of PrPC into disease associated form remains uncertain. Despite species
differences in PrP expression on blood cells (Barclay et al., 2002;
Halliday et al., 2005), the interaction of endogenous hemewith intracel-
lular PrP could occur in blood and affect the interpretation of blood-
based diagnostic tests for prions. The present study was undertaken to
test the hypothesis of prion inhibitory and peroxidase enhancing effects
associated with endogenous heme binding to cellular proteins, includ-
ing PrP, and the implications of these effects in peroxidase-linked
immuno-detection and PrPC seeded conversion assays.
2. Materials and methods
2.1. Source of samples and reagent preparation
Whole blood samples from healthy sheep (8) and chicken (1) were
collected in tubes containing EDTA up to a volume of 10mL per animal.
Negative and positive brain samples were obtained from healthy
(1) and scrapie-infected (1) sheep, from which disease status was con-
ﬁrmed by immunohistochemistry. Bovine hemin (Frontier Scientiﬁc,
Logan, UT, USA), recombinant PrP expressing sheep ARQ genetic variant
(rPrPC, AJ Analytik, Jena, Germany)were acquired commercially. A stock
solution of heme (50 mM) was prepared in dimethyl sulphoxide
(Sigma-Aldrich, Saint Louis, MO, USA) at pH 9.0, and diluted in PBS
(pH 7.4) to the desired concentration before use. Ovine rPrPC was
reconstituted to 0.1 mg/mL in PBS (pH 7.4). A 20% (w/v) stock of ovine
scrapie negative (NBH) and infectious (IBH) brain homogenatewas pre-
pared by homogenizing brain from healthy and scrapie infected sheep in
a grinding tube containing lysis buffer (Bio-Rad TeSeE® Sheep and Goat
kit, Marnes-la-Coquette, France). A 20% (w/v) stock of Tg338 mice NBH
was prepared by homogenizing brain in tissue grinder (Potter-Elvehjem,
VWR, Vineland, NJ, USA) containing conversion buffer (CB, 150mMNaCl,
1% Triton X-100 and protease inhibitor cocktail (Roche, Mannheim,
Germany) in PBS (pH 7.2)). To obtain RBC, whole bloodwas initially cen-
trifuged at 300 g for 15 min at RT, the supernatant removed. The
sedimented cells were further centrifuged (1500 g for 10 min, 4 °C) and
the middle portion of the RBC phase was diluted with the same volume
of PBS (pH 7.4), lysed with 10 volumes of ice-cold lysis buffer (5 mM
NaH3PO4, 1 mM EDTA), and centrifuged (20,000 g, 40 min, 4 °C); the su-
pernatant was used as stock of lysed RBC. The prepared samples of heme,
rPrPC and RBC were stored at−80 °C.
2.2. Sample treatments
Denaturation, heme spiking or heme degradation was applied on
designated samples before use. For denaturation, the prepared samples
were treatedwith 1Mor 4Mguanidinehydrochloride (GdnHCl; Sigma-
Aldrich, Saint Louis, MO, USA), 1:1 (v/v), and incubated at 80 °C for20 min. For spiking heme into rPrPC, NBH, IBH or RBC, samples were
mixed with various heme concentrations and incubated with end-
over-end rotation from 3 min to 1 h at RT in the dark. Treatment with
reduced glutathione (GSH) was used to degrade heme, revealing its
contribution to the heme–PrP complex-related POD. Prior to denatur-
ation, selected samples were treated with 20 mM L-Glutathione
(Sigma-Aldrich, Saint Louis, MO, USA) prepared in PBS adjusted to
pH 7.0 and POD was subsequently measured by immuno-capture
assay as described below.
2.3. Direct POD quantiﬁcation in hemoprotein complexes by TMB assay
Sample POD was measured directly through the oxidation of
3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Bio-Rad TeSeE® Sheep
and Goat Detection kit, Marnes-la-Coquette, France), by H2O2. The
same TMB substrate used in the immuno-capture assay described
belowwas added to the samples and the reactionwasmonitored for ab-
sorbance at 450 nm on a microplate reader (Bio-Rad Laboratories Ltd,
Hercules, CA, USA). Ovine rPrPC (8 μM), NBH (1%) and RBC (1:160,000)
were mixed each 1:1 (v/v) with heme (8 μM) prior to reaction with
TMB substrate. Absorbance means in resulting hemoprotein complexes
were compared to the means of heme, rPrPC, NBH or RBC spiked 1:1
(v/v) with PBS (pH 7.4).
2.4. Study of the impact of POD inherent to blood on peroxidase-based
immunodetection assay
Normal whole blood (1:5 (v/v), in PBS (pH 7.2)) from 8 sheep and 1
chickenwas used to prepare a panel of native (1:1 (v/v) in PBS (pH 7.2))
and denatured (1:1 (v/v), 4 M GdnHCl) samples, which were then sub-
jected to a previously described protocol developed for the detection
of Creutzfeldt-Jakob disease in blood (Edgeworth et al., 2011). Brieﬂy,
400 μL of each sample diluted two-fold into capture buffer (200 mM
TRIS, 4% (w/v) ratio bovine serum albumin, 4% (w/v) CHAPS, 2 tablets
complete protease inhibitor (Roche, Mannheim, Germany), 80 units
benzonase (EMD Chemicals Inc. Newark, NJ)), was added to each tube
containing 60-mg aliquots of capture matrix (CM; 45-μm stainless
steel beads, Goodfellow Cambridge Ltd, Huntingdon, England) and incu-
bated overnight with end-over-end rotation. The CM was isolated on a
magnetic rack, supernatant discarded, and after 3× wash with 1 mL of
PBS plus 0.05% v/v Tween-20 (PBST), all liquid was removed and the
capture matrix was heated (110 °C, 5 min). To each tube, 50 μL of bio-
tinylated antibody (ICSM18; D-Gen, Ltd. London, UK) prepared at
1 μg/mL in PBS plus 1% (v/v) Tween-20 (PBST*) was added and incubat-
ed (37 °C, 1 h). After 3× wash with 1 mL PBST, isolating CM each time,
each sample was incubated (37 °C, 45 min) with NeutrAvidin–HRP
(Pierce, Rockford, IL, USA) prepared at a 1:100,000 dilution in PBST*.
After 5× wash with 1 mL PBST, isolating CM each time, 60 μL of
SuperSignal ELISA Femto chemiluminescent substrate (Pierce, Rockford,
IL, USA)was added to each sample, andCMwas evenly distributed into 3
replicate wells of a black ﬂat bottom 96-well plate (Greiner Bio-One
GmbH, Frickenhausen, Germany). A further 80 μL of SuperSignal ELISA
Femto chemiluminescent substrate was added per well. Plates were
scanned with FluorStar Omega plate reader (BMG Labtech GmbH,
Ortenberg, Germany). Immunoassay was performed on blood samples
either with the HRP-conjugated NeutrAvidin, as per blood-based assay
protocol or without it. The purpose of completing the immunoassay
without conjugate was to measure the degree of substrate oxidation at-
tributed solely to the endogenous POD in samples. In these cases, the
blood-based assay protocol was slightly modiﬁed; both antibody and
NeutrAvidin–HRP were replaced with equal volumes of PBS (pH 7.4).
2.5. Study of PrP-related POD by immuno-capture assay
A previously described (Everest et al., 2006) commercial sandwich
ELISA was modiﬁed to measure PrP-associated POD in heme (2.5 M),
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(RBC5, 1:10) RBC samples. Samples of brain homogenate and RBC
were denatured (1:1 (v/v), 1 M GdnHCl), precipitated with 5-fold
volumes of pre-chilled methanol (−20 °C, 2 h) and centrifuged
(15,000 g, 20 min). The resulting pellet was resuspended in reagent C,
heated (100 °C, 5 min), diluted with sample diluent and loaded on the
microplate coated with anti-ovine PrP monoclonal antibody (Bio-Rad
TeSeE® Sheep and Goat Detection kit, Marnes-la-Coquette, France).
Immunoassay was further performed either with the HRP-conjugated
anti-ovine PrP monoclonal antibody, as per manufacturer's recom-
mendations or without it. The purpose of completing the immunoas-
say without secondary antibody was to avoid the interference of
conjugate-derived HRP activity with endogenous POD in samples. In
these cases, themanufacturer's protocolwasmodiﬁed by omitting incu-
bation of the microplate with the conjugated antibody.
2.6. The effect of heme on the structural conversion of PrPC by PMCA
To investigate the seeded conversion of PrPC, incubated with or
without heme, we adapted the previously described protein misfolding
cycling ampliﬁcation (PMCA) assay (Saborio et al., 2001) by preparing
heme-supplemented substrates in CB. Each of the 98-μL substrates
was composed of Tg338 mice brain homogenate (20% w/v) mixed
with equal volume of 1 μM, 10 μM, 100 μM or 1000 μM heme or with
CB only. Reactions prepared in 0.2 mL PCR tubes in three replicates
were seeded with the 2 μL IBH (20%w/v) in PBS (pH 7.2) and subjected
to three PMCA rounds. Each PMCA roundhad 48 PMCA cycles composed
of an incubation (29 min 20 s, 37 °C) and sonication (40 s, power level
80%) using theMisonix 4000 (Misonix, NY, USA). After a 3-fold dilution
of the ampliﬁed sampleswith designated fresh substrate, a second and a
third round of PMCA was performed. Resulting pre- and post-PMCA
samples were collected and stored at −80 °C. Presence of PrPres iso-
forms in those samples was measured in triplicate using the Bio-Rad
TeSeE® Western Blot kit following the manufacturer's recommenda-
tions, as previously described (Arsac et al., 2009). Image acquisition
and densitometric analysis of PrPres were performed using ChemiDoc
XRS imaging system and Quantity One® image analysis software
(Bio-Rad Laboratories Ltd, Hercules, CA, USA). Band intensity means
of hemin-treated were compared versus untreated samples.
Unpaired two-tailed t-tests were used for all comparisons. The
differences were considered statistically signiﬁcant if P b 0.05. All
experiments were conducted at least three times. Figures include
means ± standard deviation (SD).
3. Results
3.1. Enhanced POD in hemoprotein complexes
Since hemoprotein complexes are known for their catalytic potential
(Das and Hecht, 2007), we sought to quantify the enhancement of POD
following the interactions of heme with PrPC, NBH and RBC. In the TMB
assay, combining commercial heme and recombinant ovine PrPC en-
hanced intrinsic peroxidase activity by 2.5-fold compared to heme
alone (Fig. 1A). Similar results were obtained by Lee et al. (2007). The
inherent oxidative properties of heme were also enhanced (P b 0.05)
following its spiking into NBHor RBC (Fig. 1B), whichmay have resulted
from the interaction of heme with intracellular proteins including PrPC.
3.2. Effects of POD inherent to blood on peroxidase-based immunodetection
To screen for oxidation activity in blood samples and test our hy-
pothesis about the impact of POD on the speciﬁcity of peroxidase-
based immunodetection, we used a prototype blood-based variant
Creutzfeldt–Jakob disease assay that utilizes the afﬁnity of PrP to
metal surfaces. Since denatured hemoproteins showed increased oxida-
tion activity (Eriksson et al., 1971; Yamada et al., 2002) we tested apanel of samples, consisting of both native and denatured normal
blood from 8 sheep and 1 chicken. Experimental data for the blood-
based assay are shown in Fig. 2 and demonstrate that denaturation
increased (P b 0.001) the average signal in samples tested with conju-
gate by 4-fold. Analyzing the results of this blood-based prion
immunodetection assay, we found that over 84% of the average signal
generated by denatured samples testedwith conjugatewas still present
when these samples were tested without conjugate. We deduced
that this 84% oxidation of luminol-based substrate in the prion
immunodetection assay was a result of POD inherent to blood. The
levels of POD detected in chicken blood were consistent with those ob-
served in ovine blood under the conditions tested in this assay (data not
shown). It was also observed that the signal of native blood samples
tested with conjugate was higher (P b 0.001) compared to the signal
of the same samples tested without conjugate. We conclude that this
differencewas attributed to the speciﬁc reaction of ovine prionswith bi-
otinylated antibody and NeutrAvidin–HRP conjugate. This provides ev-
idence that PrP have been captured onmetal surfaces, therefore the POD
observed in denatured samples can be PrP-associated.
3.3. PrP-associated and heme-derived POD in RBC
An ELISA-based immuno-capture assaywas used to investigate if the
POD observed in denatured blood samples co-puriﬁed with PrP. The
POD associated with non-ovine, ovine RBC and brain prions captured
on a microplate previously coated with anti-ovine PrP antibody
(Fig. 3) was measured. The POD, previously detected by the blood-
based assay on denatured ovine whole blood samples (Fig. 2), was
also detected by immuno-capture assay in denatured ovine RBC sam-
ples. However, the immuno-capture assay did not detect POD in dena-
tured heme or non-ovine blood that was reactive in the blood-based
assay. These results demonstrate the speciﬁcity of binding of the
sheep RBC samples to the ELISA plates and provide evidence that
there was no non-speciﬁc binding of the peroxidase-active complexes
to the plate surface. Next, using the sandwich ELISA, only ovine RBC
(1, 2, 3 & 4), NBH and IBH samples showed signal, which indicates
that TMB oxidation was catalyzed by endogenous or conjugate-
derived peroxidase complexes with ovine PrP. ELISA shows that in the
case of blood samples, 100% of oxidation was attributed to the intrinsic
POD, while in the case of NBH and IBH it was mainly due to the
conjugate-derived HRP. The intrinsic POD is inherent to a hemoprotein
complex and its level may not always correlate with the amount of a
sole protein or heme. As a result, low POD and high PrP signal in NBH
and IBH can be attributed to the fact that brain PrP captured on the
ELISA plate may not have sufﬁcient endogenous heme to form a hemo-
protein complex with PrP and to induce POD.
To determine if the PrP-copuriﬁed POD previously found by immu-
noassay was a product of PrP interactions with heme, selected samples
were treated with the GSH prior to denaturation. The objective of GSH
treatment was to show that the POD activity attributed to the heme–
PrP complex can be inhibited by removing heme. The result of that
treatment on RBC samples was a 75% to 98% reduction of PrP-related
POD (Fig. 3).
3.4. Resistance to abnormal structural changes in heme-enriched PrPC
seeded conversion
To investigate the inﬂuence of heme on the aggregation of PrPC
monomers,we used a PMCA-based seeded conversion assay in the pres-
ence or absence of heme. Cell-free conversion of PrPC to PrPSc by natural
porphyrins was inhibited at concentrations between 10 μM and
1000 μM, but not at 1 μM of heme (Fig. 4, A & B). A signiﬁcant
(P b 0.05) depression of aggregation of PrPC in 20% (w/v) Tg338 mice
brain homogenate was observed with as low as 10 μMheme, beginning
the 2nd PMCA round and increasing throughout the 3rd PMCA round in
Fig. 1. Direct POD measurement by TMB assay in hemoprotein complexes. Ovine rPrP (8 μM) (A) or NBH (1%) and RBC (1:160,000) (B) was mixed 1:1 (v/v) with heme (8 μM) prior to
reaction with TMB substrate monitored by absorbance at 450 nm as a function of time. Signal of hemoprotein was compared to heme, rPrP, NBH or RBC spiked 1:1 (v/v) with PBS
(pH 7.4). Data shown are means of 3 replicates; SD ranged between 0.001 and 0.044 for all treatments. Absorbancemeans of rPrP, NBH and RBC differ signiﬁcantly (P b 0.05) from absor-
bance means of corresponding hemoprotein complexes at the ﬁnal time point.
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presence of heme was found to prevent formation of prion aggregates.
4. Discussion
Prion inhibitory and peroxidase enhancing effects resulting from the
binding of PrP to natural or synthetic porphyrins have been reported.
Several studies have shown that synthetic porphyrins inhibit the con-
version of PrPC to PrPSc (Caughey et al., 1998) and reduce formation of
PrPSc in scrapie-infected cells (Caughey et al., 2007; Raymond et al.,
2006). Recently it has been demonstrated that the interaction of free
hemin with PrPC enhanced the inherent POD of heme (Lee et al.,
2007). The current study investigated if the observed effects could be
associated with endogenous heme binding to intracellular proteins, in-
cluding PrP, and interfere with peroxidase-linked immuno-detection
and cell-free conversion of prions. We provide evidence that when ex-
posed by denaturation, PrP-boundheme enhanced POD in blood and in-
terfered with peroxidase-linked immunodetection of prions in a blood-
based assay. In addition to enhancing POD, the binding of PrPC with
heme at a suitable ratio inhibited the in vitro conversion of PrPC into ab-
normal form. For the ﬁrst time, to our knowledge, this study has showna natural porphyrin to possess a protective anti-PrPSc effect. These
results support previous ﬁndings, including the anti-PrPSc activity of
synthetic porphyrins (Caughey et al., 1998) and increased POD and pre-
vention of ﬁbril formation in the heme–amyloid-β complex (Atamna
and Boyle, 2006).
Peroxidase activity has been studied in RBC of different species
(Anderson et al., 1978; Paglia and Valentine, 1967). The RBC are a
major reservoir for heme in animal and human blood (Grinstein et al.,
1959; Nagy et al., 2010) and some heme may interact non-speciﬁcally
with membrane proteins such as serum albumin and hemopexin in-
cluding PrP. Hemoproteins have been known for their catalytic potential
(Das and Hecht, 2007). Consistent with previous results (Lee et al.,
2007), we also observed that direct interaction between free heme
and PrPC enhanced intrinsic POD. Additionally, using a blood-based
assay developed for Creutzfeldt–Jakob disease diagnostics, we observed
that denatured ovine blood samples showed markedly higher signal
compared to native blood. Very little of that signal was attributable to
the antibody conjugated HRP andmost of the difference was due to en-
dogenous POD. In support of previous ﬁndings (Eriksson et al., 1971;
Yamada et al., 2002), our results suggest that blood solubilization and
denaturing with chaotropes may have unfolded peptide chains and
Fig. 2. Endogenous POD in native (■) or denatured (□, 4 M GdnHCl) normal blood sam-
ples measured by blood-based immunoassay with HRP conjugate or without it. Data
shownare themean chemiluminescent signal of 8 ovine and 1 chicken blood samples test-
ed in triplicate and are expressed as a ratio relative to the baseline value (three SDs greater
than the mean chemiluminescent signal for native blood samples tested with conjugate;
dashed line). aDenaturation enhanced (P b 0.001) the signal intensity in samples tested
with conjugate by an average of 4-fold, and over 84% of this signal was observed in dena-
tured samples testedwithout conjugate. bDifference (P b 0.001) between signals of native
samples tested with conjugate vs. signals in those samples tested without conjugate was
attributed to the speciﬁc reaction of ovine prions with biotinylated antibody and
NeutrAvidin–HRP conjugate. Error bars show SDs.
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complexes, including heme–PrP, resulting in increased oxidation activ-
ity. The prototype blood-based assay used in this study incorporates
a step of sample binding with the stainless steel beads prior to
immunodetection. Previous studies of the afﬁnity of PrP to metal sur-
faces revealed that stainless steel beads bind avidly both PrPSc and
PrPC (Luhr et al., 2009). In our blood-based assay study, bound to the
metal powder, PrPC in complex with heme may contribute to the
enhanced POD and the resulting oxidation of the chemiluminescent
substrate. Results of our ELISA-based immuno-capture assay using
anti-ovine PrP antibody further conﬁrmed that POD observed in the de-
natured ovine RBC was PrP-related.Fig. 3.PrP-associated and heme-derived PODmeasuredby ELISA-based immuno-capture assay
(RBC1 to RBC4, 1:10) and 1 chicken (RBC5, 1:10) RBC. Before loading on themicroplate coatedw
recovered by centrifugation. When applied, GSH (20 mM) treatment preceded denaturation anIn order to providemore evidence that the POD observed in our study
was a product of endogenous heme binding to intracellular PrPC, we used
heme decomposition with GSH to inhibit hemoprotein-related POD.
Because GSH has been shown previously to extract heme from RBC
(Shviro and Shaklai, 1987) and to degrade heme associated with the cell
membrane (Atamna andGinsburg, 1995),we anticipated that it could de-
stroy heme in the hemoprotein complex as well. Based on the results of
heme degradation with GSH, we presumed that 75% to 98% of the PrP-
related POD observed in RBC samples in ELISA-based immuno-capture
assay was attributed to endogenous heme complex with PrPC.
In both native and denatured brain homogenate, signal attributed to
the PrP-related POD was negligible. These results seem to indicate that
endogenous POD effects are not observed in brain tissue.We hypothesize
that the extent of POD enhancement may be proportional to the local
heme to PrP ratio. In order for the brain to reach POD activity similar to
RBC, the ratio of heme to PrP in brain may need to be stoichiometrically
the same as the ratio of heme to PrP in RBC. The physiological function
of PrP is related to cellular antioxidant defenses (Klamt et al., 2001),
which were found altered in scrapie-infected brains (Wong et al., 2001).
Our results provide evidence that PrP canmodulate the peroxidase activ-
ity of heme. We hypothesize that in vivo, thermodynamically activated
heme–PrP complex can acquire catalytic ability and play a role of an anti-
oxidant that inhibits oxidation reactions and prevents PrPSc aggregation.
The PrP structural changes by PMCA experiment revealed that at
suitable concentrations, natural porphyrins can prevent formation of
PrPSc. These results can explain the recently observed inhibition of
PMCA by RBC (Lacroux et al., 2014). Our study also showed a dose-
dependent inhibition pattern. We speculate that the RBC may not dis-
seminate PrPSc because endogenous heme has a potential to depress
misfolding of local PrP isoforms. The suggested mechanism involved
in protein protection against self-aggregation in heme–PrP complex
can be similar to the ﬁbril destabilization by antioxidant compounds
(Ono and Yamada, 2006), prevention of amyloid-β aggregation
(Atamna and Boyle, 2006; Khodarahmi et al., 2010) or stimulation of
the internalization of PrP (Lee et al., 2007) by heme, the control of
prion accumulation by synthetic porphyrins (Caughey et al., 1998) or
by masking of essential PrP epitopes (Abdallah et al., 2012).
It remains to be established to what extent the interaction between
heme and PrP occurs in vivo, during PrP biogenesis or its endocytic traf-
ﬁcking. Based on the idiosyncratic folding behavior of heme-linked pro-
teins (Garcia et al., 2005), we do not discard the possibility that the PrPwith (□) andwithout (■) HRP conjugate inheme (2.5M), NBH and IBH (both 20%), 4 ovine
ith anti-PrP antibody, sampleswere denatured (1MGdnHCl), methanol-precipitated and
d high PK proteolysis (seeMaterials and methods). Data shown are mean ± SD (n = 3).
Fig. 4. Cell-free conversion of PrPC to PrPSc conducted by PMCA on substrates composed of Tg338 mice brain homogenate with designated concentrations of heme (see Materials and
methods). Decline in PMCA efﬁciency was a result of heme depression of PrP aggregation. (A) Image of the total PrPres in the PK-digested reaction products (shown is one representative
example in 3 experiments). (B) Graphs of the quantitated PrPres products. Statistical signiﬁcance of thedifferences between themean of heme-treated vs. untreated samples is indicated by
* (P b 0.05), ** (P b 0.01), or *** (P b 0.001). In all the treatments SD was between 11 and 30 (pre-PMCA), 15 and 60 (PMCA-1), 60 and 300 (PMCA 2 & 3).
173A. Soutyrine et al. / Research in Veterinary Science 101 (2015) 168–174conformation in RBC determined by prosthetic groupmay be more sta-
ble thermodynamically and differ from PrP conformations found else-
where. The effect of heme on PrPC conversion may explain why RBC
do not become infected during prion disease. In neuronal tissue, the
protective mechanism may not be as efﬁcient as in blood probably be-
cause of a lower heme to PrP ratio. The extent to which physiological
porphyrins canmodulate prion disease progression warrants investiga-
tion by disease transmission studies. The speculative detoxiﬁcation role
of heme–PrP complex in the regulation of free heme surplus and in the
protection of tissues against heme-mediated toxicity (Kumar and
Bandyopadhyay, 2005) is also of potential interest.
We conclude that, i) direct interaction between heme and PrP leads
to enhanced peroxidase activity; ii) the interaction between PrP and
heme inhibits the conversion of PrPC to PrPSc, and iii) the observed ef-
fects can interfere with peroxidase-linked immuno-detection and PrPC
seeded conversion in blood-based detection assays. Our ﬁndings further
suggest that the endogenous POD detected in denatured blood and RBC
can be the result of an increased exposure of PrP-bound heme group.
Ultimately, these ﬁndings have implications for the development of
blood-based diagnostic assays, requiring consideration for the potential
of heme to interfere with peroxidase-based detection systems and the
inhibition of PrPC seeded conversion.
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